Key result
Apixaban linked to ~34% lower stroke risk and less bleeding versus warfarin in hemodialysis.
Why the study?
Patients with kidney failure on hemodialysis and atrial fibrillation are at high risk of ischemic stroke, and while oral anticoagulation may reduce this risk at the expense of excess bleeding, the comparative effectiveness of apixaban versus warfarin initiation in this population needed evaluation.
Does initiation of apixaban compared with warfarin reduce ischemic stroke and clinically important bleeding in patients with kidney failure on hemodialysis and newly diagnosed atrial fibrillation?
Cohort (n=7,956)
Yes
Does initiation of apixaban compared with warfarin reduce ischemic stroke and clinically important bleeding in patients with kidney failure on hemodialysis and newly diagnosed atrial fibrillation?
In a target trial emulation of patients on hemodialysis with newly diagnosed atrial fibrillation, initiating apixaban was associated with significantly lower risks of both ischemic stroke and clinically important bleeding compared with initiating warfarin.
Answers are grounded in this paper and cite their sources.
May support apixaban preference in hemodialysis AF; extends observational data but leaves randomized confirmation open.
Patients with kidney failure on hemodialysis (KFHD) and atrial fibrillation (AF) are at high risk of ischemic stroke. Oral anticoagulation (OAC) may reduce this risk but at the expense of excess bleeding. We emulated a randomized comparative effectiveness trial of apixaban versus warfarin initiation in patients with KFHD and newly diagnosed AF. Trial emulation embedded in the US Renal Data System. Medicare-insured patients with KFHD and newly diagnosed AF without recent OAC use (2014-2019). Initiation of apixaban versus warfarin within 30 days from AF diagnosis. Ischemic stroke, clinically important bleeding (co-primary outcomes). Other thromboembolic and bleeding events, death (secondary). We compared propensity-matched new users of apixaban and warfarin using Cox proportional hazards models. Among previously OAC-naïve patients with KFHD and newly diagnosed with AF, 3985 initiated apixaban and 6426 initiated warfarin. Propensity matching 3978 apixaban users with 3978 warfarin users balanced all measured characteristics. Median CHA2DS2-VASc score was 4 (IQR: 3-5). Apixaban was initiated a median 6 (IQR: 3-12) days after AF and used for a median 58 (IQR:37-135) days; warfarin was initiated a median 5 (IQR: 2-12) days after AF and used for a median 93 (IQR:38-238) days. In intention-to-treat analyses, rates of ischemic stroke were 34% lower (HRITT=0.66; 95%CI, 0.47-0.94; p=0.02) and rates of clinically important bleeding were 28% lower (HRITT=0.72; 95%CI, 0.63-0.83; p<0.001) in patients who initiated apixaban. All-cause mortality did not differ between groups; neither did negative control outcomes of hip fracture and pneumonia. Results were robust when restricting analyses to patients with CHA2DS2-VASc score of ≥2. Potential for residual confounding. Initiating apixaban soon after newly diagnosed AF was associated with lower risks of ischemic stroke and clinically important bleeding compared with initiating warfarin.
No takes yet. Share an insight, caveat, or question.
Winkelmayer et al. (2026) conducted a cohort in Kidney failure on hemodialysis with newly diagnosed atrial fibrillation (n=7,956). Apixaban initiation within 30 days from AF diagnosis vs. Warfarin initiation within 30 days from AF diagnosis was evaluated on Ischemic stroke and clinically important bleeding (co-primary outcomes) (HR 0.66 for ischemic stroke; HR 0.72 for clinically important bleeding, 95% CI 0.47-0.94, p=0.02). Apixaban initiation versus warfarin in hemodialysis patients with new AF lowered risks of ischemic stroke and clinically important bleeding.
Synapse has enriched 10 related papers. Consider them for comparative context: